Niki BioSolutions, Inc. (NIKI) Diversifiers

Equity · Currency in USD · Last updated Jul 22, 2026

Niki BioSolutions, Inc. (formerly Aptorum Group Limited, merged with DiamiR Biosciences in July 2026) is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases, alongside a brain-health diagnostics pipeline. Its pipeline includes SACT-1, in Phase 1 trials for neuroblastoma and other cancers; ALS-4, in Phase 1 trials for bacterial infections including MRSA, tuberculosis, and pseudomonas aeruginosa; and several preclinical candidates including SACT-COV19, SACT-2, SACT-3, ALS-1, and ALS-2/3. The company is headquartered in London, United Kingdom, and trades on the Nasdaq Capital Market.

Looking to balance out your exposure to NIKI? The ETFs below have the lowest correlation with NIKI — they tend to move on their own, which can help reduce risk when NIKI drops. The stock ideas table highlights individual companies that behave independently from NIKI.

No Diversifiers Found for NIKI

We do not have enough correlation history to rank diversifiers for this symbol yet.

Diversification Analysis

Build a portfolio that complements NIKI

Add NIKI to the Diversification Analyzer to see how it overlaps with your other holdings and which assets balance it best.

Analyze a portfolio with NIKI